The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company, except to the extent that the reverse stock split ...
6d
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...
HCW Biologics received an extension from Nasdaq to regain compliance with listing rules by April 25 and June 15, 2025. HCW Biologics Inc., a clinical-stage biopharmaceutical company focused on ...
HCW BIOLOGICS ($HCWB) is expected to release its quarterly earnings data on Tuesday, April 1st after market close, per Finnhub. Analysts are expecting revenue of ...
HCW Biologics, Inc MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company ...
HCW Biologics (HCWB) announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock, par value ...
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical ...
HCW Biologics Inc. announced the approval of a reverse stock split following a Special Meeting of Stockholders on March 31, 2025. The pharmaceutical company, currently trading at $0.28 with a ...
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen ...
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback